Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	3.73B +14.6%
Revenue (ttm)	724.20M -9.4%
Net Income	121.15M -26.6%
EPS	2.37
Shares Out	51.15M
PE Ratio	30.82
Forward PE	25.17
Dividend	0.94 (1.28%)
Ex-Dividend Date	Jul 14, 2025

Volume	53,007
Average Volume	106,928
Open	72.55
Previous Close	73.00
Day's Range	71.85 - 73.00
52-Week Range	45.52 - 74.30
Beta	0.24
RSI	70.16
Earnings Date	Feb 25, 2026

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,188
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.